Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

Valley Children nontraditional model expands pediatric access through partnerships and outpatient growth across California's ...

If you have not had a chance to review our quarterly earnings release, it can be found on our website at seraprognostics.com.

The eighth-generation Lexus ES is now on sale, with the long-running luxury sedan's first-ever battery-electric (BEV) models ...

Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...

Boeing engineers Kevin Kwak (foreground) and Klaus Okkelberg confer with fellow team members Arvel Chappell III and Andrew Riha (both on-screen), who worked together to prototype a large language ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...

The Food and Drug Administration plans to select about 40 devices not yet cleared by the agency to receive special agency discretion to participate in the new chronic care Advancing Chronic Care with ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

In 2018, the California state legislature set the goal of reaching net-zero carbon emissions by 2045 in the California Climate Crisis Act. In September of 2025, a team of Stanford researchers ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...